iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Rx and market share trends for key US products: IIFL Securities

12 Jul 2022 , 11:47 AM

Key takeaways include:

  • Cipla’s steady ramp-up in Albuterol continued in Q1FY23, with its market share (MS) improving to 18.5% (till 24-Jun) versus 17.6% in Q4FY22; however, over the last 5 weeks, Hikma’s MS improved sharply from 0.5% to 2.3% largely at the expense of Cipla’s MS.

 

  • Within 4 months of launch, Cipla captured 4.2% MS in Lanreotide through its 505(b)(2) product.

 

  • Lupin’s MS in Brovana declined from ~25% to ~22% during the first six months of 2022.

 

  • Sun and Alembic received USFDA approval for generic Brovana in May 2022. While Sun will manufacture Brovana at its Baska facility, Alembic will source the same from Holopack (CMO).

 

  • Sun’s specialty products are showing robust traction, with Ilumya/Cequa’s integrated units (IU) volumes growing 50%/63% YoY and 4.4%/11% QoQ, resp., while Winlevi’s weekly TRx runrate improved 6% QoQ. Sun’s US generic business will be aided by recent complex generic approvals of Ambisome and Pentasa.

 

  • Dr Reddy’s has the highest 16.7% MS among generics in Vascepa, followed by Hikma/Apotex with 12.3%/7.9% MS, respectively.

 

  • Generic Suboxone from Apotex can further accelerate Dr Reddy’s declining MS in US. During 1HCY22 (till 24-Jun), Dr Reddy’s MS is down from 20.5% to 19%.

 

  • Within 4 months of launch in the US, Torrent Pharma captured 50% of IU volumes in Aczone through its own and Mayne Pharma’s distribution network.

 

  • To arrest declining MS in Insulin Glargine in the US, Sanofi launched unbranded version of Lantus, which can potentially slow down Biocon’s MS ramp-up.

 
IIFL Securities’ top picks: Cipla, Gland Pharma, JB Pharma and Alkem.

Related Tags

  • Alkem
  • Cipla
  • Gland Pharma
  • JB Pharma
  • Pharma
  • prescription volumes
  • Sun Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Awfis IPO oversubscribed 4.19x on day two
23 May 2024|09:51 PM
Indian markets end the day on high
23 May 2024|03:59 PM
Markets surge

Markets surge

Whatsapp
Facebook
Twitter
LinkedIn
23 May 2024|03:45 PM
MG Motor India to supply 3000 EVs to Vertelo
23 May 2024|03:46 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.